Exclusion Reasons Presumption of Long- Term Non-Acute Administration C9399 Unclassified Drugs or

Size: px
Start display at page:

Download "Exclusion Reasons Presumption of Long- Term Non-Acute Administration C9399 Unclassified Drugs or"

Transcription

1 Noridian Healthcare Solutions, LLC Jurisdiction F Part B Self-Administered Drug (SAD) Exclusion List (A53033); Effective 8/7/2017 The following medications are considered self-administered and are not payable under Medicare Part B. Coverage may be provided under Medicare Part D. The most current version of this list may be accessed at med.noridianmedicare.com under Policies. The Noridian Contractor Medical Directors (CMDs) review the list on an ongoing basis and may update and republish at their discretion. Code Generic Name Brand Name Effective Date Apparent On Its Face Exclusion Reasons Presumption of Long- Term Non-Acute Administration Tanzeum (albiglutide SQ) 6/4/2015 X X Myalept (metreleptin) 6/4/2015 X X Signifor (pasireotide) 6/4/2015 X X Rebif (interferon beta 1a) 6/4/2015 X X Bydureon (exanatide XR) 6/4/2015 X X Cosentyx (secukinumab) 6/4/2015 X X Praluent (alirocumab) 11/24/2015 X Repatha (evolucumab) 11/24/2015 X Trulicity (dulaglutide) Acceptable Evidentiary Criteria Available

2 C9399 Unclassified Drugs or Otrexup, Rasuvo (methotrexate solution auto-injector nonchemotherapeutic) Natpara (parathyroid hormone) Plegridy (pedinterferon beta-1a) Toujeo (insulin glargine injection) Byetta (exenatide) Erelzi (etanercept-szzs) 12/6/2016 X Strensiq (asfotase-alfa) 2/28/2017 X Zinbryta (daclizumab) 2/28/2017 X Taltz (ixekizumab) 2/28/2017 X Amjevita (adalimumab-atto) 2/28/2017 X Dupixent (dupilumab) 8/7/2017 X Siliq (brodalumab) 8/7/2017 X J0135 Injection, Adalimumab, 20 Mg Humira 11/1/2003 X X J0270 Injection, Alprostadil, 1.25 Alprostadil, Caverject, Edex, 1/15/2003 X X Mcg (Code May Be Used For Prostin VR Pediatric Medicare When Drug Administered Under The

3 J0364 J0630 Injection, Apomorphine Hydrochloride, 1 Mg Injection, Calcitonin Salmon, Up To 400 Units Apokyn 6/4/2015 X X Calcimar, Miacalcin, Osteocalcin, Salmonine, Fortical 1/15/2003 X X H. P. Acthar 6/26/2013 X X J0800 Injection, Corticotropin, Up To 40 Units J1324 Injection, Enfuvirtide, 1 Mg Fuzeon 5/1/2004 X X J1438 Injection, Etanercept, 25 Mg Enbrel 1/15/2003 X X (Code May Be Used For Medicare When Drug Administered Under The J1559 Injection, Immune Globulin Hizentra 2/15/2011 X X (Hizentra), 100 Mg J1595 Injection, Glatiramer Acetate, Copaxone 5/1/2004 X X 20 Mg J1675 Injection, Histrelin Acetate, 10 Supprelin LA 7/15/2006 X X Micrograms J1744 Injection, Icatibant, 1 Mg Firazyr 7/31/2012 X X J1815 Injection, Insulin, Per 5 Units Humalog, Humalog Mix 11/1/2003 X X 50/50, Humulin N. Humulin R, Lantus, Levemir, Novolin 70/30, Novolin N. Novolin R. Novolog, Novolog Flexpen, Novolog Penfill J1817 Insulin For Administration Through Dme (I.E., Insulin Pump) Per 50 Units Humalog, Humulin R, Novolin R, Novolog, Novolog Flexpen, Novolog Penfill 1/15/2003 X X J1830 Injection, Interferon Beta-1b, 0.25 Mg (Code May Be Used Betaseron 1/15/2003 X X

4 For Medicare When Drug Administered Under The J2170 Injection, Mecasermin, 1 Mg Increlex, Iplex 4/15/2007 X X J2212 Injection, Methylnaltrexone, Relistor 9/30/2013 X X J Mg Injection, Octreotide, Non- Depot Form For Subcutaneous Or Intravenous Injection, 25 Mcg Sandostatin, Ocreotide Acetate 10/15/2005 X J2440 Injection, Papaverine Hcl, Up Papaverine HCL 11/1/2003 X X To 60 Mg J2940 Injection, Somatrem, 1 Mg Protropin 1/15/2003 X X J2941 Injection, Somatropin, 1 Mg Humatrope, Genotropin, Omnitrope, Saizen, Zorbtive, Zomacton, Norditropin, Nutropin 1/15/2003 X X J3030 Injection, Sumatriptan Succinate, 6 Mg (Code May Be Used For Medicare When Drug Administered Under The Imitrex 1/15/2003 X X J3110 Injection, Teriparatide, 10 Mcg Forteo 11/1/2003 X J3355 Injection, Urofollitropin, 75 Iu Metrodin, Bravelle, Fertinex 4/15/2007 X X J3490 Unclassified Drugs Peginterferon Alfa 2-b, 6/26/2013 X X Sylatron, Pegintron J3490 Unclassified Drugs Kynamro (mipomersen 6/26/2016 X X sodium) J3490 Unclassified Drugs Pramlintide acetate, Symlin, SymlinPen 60, SymlinPen 4/1/2006 X X

5 120 J3490 Unclassified Drugs Byetta (exenatide) 4/1/2006 X X J3490 Unclassified Drugs Egrifta, Tesamorelin Acetate 9/30/2013 X X J3490 Unclassified Drugs Trimix 9/30/2013 X X J3490 Unclassified Drugs Victoza, Saxenda, Liraglutide 9/30/13 X X GLP-1 J3490 Unclassified Drugs Tanzeum (albiglutide SQ) 6/4/2015 X X J3490 Unclassified Drugs Myalept (metreleptin) 6/4/2015 X X J3490 Unclassified Drugs Signifor (pasireotide) 6/4/2015 X X J3490 Unclassified Drugs Rebif (interferon beta 1a) 6/4/2015 X X J3490 Unclassified Drugs Bydureon (exanatide XR) 6/4/2015 X X J3490 Unclassified Drugs Cosentyx (secukinumab) 6/4/2015 X X J3590 Unclassified Biologics Praluent (alirocumab) 11/24/2015 X J3590 Unclassified Biologics Repatha (evolucumab) 11/24/2015 X J3590 Unclassified Biologics Trulicity (dulaglutide) J3590 Unclassified Biologics Otrexup, Rasuvo (methotrexate solution auto-injector nonchemotherapeutic) J3590 Unclassified Biologics Natpara (parathyroid hormone) J3590 Unclassified Biologics Plegridy (pedinterferon beta-1a) J3590 Unclassified Biologics Toujeo (insulin glargine injection) J3590 Unclassified Biologics Pegvisomant Somavert 5/1/2004 X X J3590 Unclassified Biologics Pegasys, Roferon-A 5/1/2005 X X (peginterferon Alfa-2a) J3590 Unclassified Biologics Kineret (anakinra) 10/15/2005 X X J3590 Unclassified Biologics Simponi (golimumab) 9/30/2013 X X J3590 Unclassified Biologics Orencia (abatacept) 9/30/2013 X X J3590 Unclassified Biologics Erelzi (etanercept-szzs) 12/6/2016 X J3590 Unclassified Biologics Strensiq (asfotase-alfa) 2/28/2017 X

6 J3590 Unclassified Biologics Zinbryta (daclizumab) 2/28/2017 X J3590 Unclassified Biologics Taltz (ixekizumab) 2/28/2017 X J3590 Unclassified Biologics Amjevita (adalimumab-atto) 2/28/2017 X J3590 Unclassified Biologics Dupixent (dupilumab) 8/7/2017 X J3590 Unclassified Biologics Siliq (brodalumab) 8/7/2017 X J9212 Injection, Interferon Alfacon- Infergen 11/1/2003 X X 1, Recombinant, 1 Microgram J9213 Injection, Interferon, Alfa-2a, Roferon-A 11/1/2003 X X Recombinant, 3 Million Units J9216 Injection, Interferon, Gamma 1-B, 3 Million Units Actimmune 1/15/2003 X X J9218 Leuprolide Acetate, Per 1 Mg Leuprolide Acetate inj 1/15/2003 X X Q0515 Injection, Sermorelin Acetate, Geref 4/15/2007 X X 1 Microgram Q3027 Injection, Interferon Beta-1a, Avonex, Avonex Pen 6/4/2015 X X 1 Mcg For Intramuscular Use Q3028 Injection, Interferon Beta-1a, 1 Mcg For Subcutaneous Use N/A 6/4/2015 X X Visiant conducts organization determinations and reconsiderations on behalf of Premera Blue Cross.

Descriptor Brand Name. Alprostadil, Caverject, Edex, Prostin VR Pediatric. Calcimar, Miacalcin

Descriptor Brand Name. Alprostadil, Caverject, Edex, Prostin VR Pediatric. Calcimar, Miacalcin Self-Administered Drug Exclusion List R2 This article from Medicare A News, Issue 2106 dated January 23, 2013 and Medicare B News, Issue 283 dated January 23, 2013 is being revised to add Acthar ACTH gel

More information

SELF-ADMINISTERED MEDICATIONS LIST

SELF-ADMINISTERED MEDICATIONS LIST SELF-ADMINISTERED MEDICATIONS LIST Table of Contents Page Last Updated: January 23, 2019 INSTRUCTIONS FOR USE... 1 APPLICABLE CODES... 1 Related Commercial Policy LIST HISTORY/REVISION INFORMATION... 5

More information

MDwise Self-Administered Codes for Medical

MDwise Self-Administered Codes for Medical The following codes are associated with medications that can be self-administered by the patient or a caregiver. As a result, MDwise will transfer coverage of these self-administered medications exclusively

More information

RAHF PFM ALPHANINE SD COAGULATION FACTOR IX J7193 COAGULATION FACTOR IX (RFIXFC)

RAHF PFM ALPHANINE SD COAGULATION FACTOR IX J7193 COAGULATION FACTOR IX (RFIXFC) INFECTIOUS DISEASE ACTIMMUNE INTERFERON GAMMA 1B J9216 ADVATE RAHF PFM ONCOLOGY ORAL AFINITOR EVEROLIMUS J7527 INFECTIOUS DISEASE ALFERON N INTERFERON ALFA N3 J9215 ALPHANATE VWF J7186 ALPHANINE SD J7193

More information

List of Designated High-Cost Drugs

List of Designated High-Cost Drugs List of Designated High-Cost Drugs UPDATED APRIL 25, 2018 For details on the High-Cost Drug policy, see Section 5.8 of the PharmaCare Policy Manual. Recent updates appear in red. Deletions are listed at

More information

Self-Injected Medications and Disposal Recommendations

Self-Injected Medications and Disposal Recommendations Actimmune (interferon gamma 1b) Apokyn (apomorphine hydrochloride) Arixtra (fondaparinux) Avonex (interferon beta 1a) Betaseron (interferon beta 1b) Copaxone (glatiramer acetate) Edex (alprostadil) InterMune

More information

METABOLIC, IMMUNE DISORDERS OR INHERITED RARE DISEASE ALPHA-1 PROTEINASE INHIBITORS ARANESP BLOOD CELL DEFICIENCY ARANESP ARCALYST

METABOLIC, IMMUNE DISORDERS OR INHERITED RARE DISEASE ALPHA-1 PROTEINASE INHIBITORS ARANESP BLOOD CELL DEFICIENCY ARANESP ARCALYST PRIOR AUTHORIZATION LIST (SUBJECT TO CHANGE) MEDICATION THERAPEUTIC CATEGORY MODULE ACTEMRA INFLAMMATORY CONDITIONS ACTEMRA ADCIRCA PULMONARY HYPERTENSION PDE-5 INHIBITORS FOR PAH ADDYI SEXUAL DISORDERS

More information

Formulary Changes. One mission: you TABLE A. FORMULARY CHANGES 7/1/2018: Commercial 3-Tier Formulary. Commercial 4-Tier Formulary

Formulary Changes. One mission: you TABLE A. FORMULARY CHANGES 7/1/2018: Commercial 3-Tier Formulary. Commercial 4-Tier Formulary One mission: you Changes July 1, 2018 Blue Cross of Idaho reviews its formularies (covered drug lists) periodically to allow members access to new drugs and to provide safe, cost effective options for

More information

LIST OF DRUGS THAT MAY BE COVERED UNDER YOUR MEDICAL BENEFIT

LIST OF DRUGS THAT MAY BE COVERED UNDER YOUR MEDICAL BENEFIT LIST OF DRUGS THAT MAY BE COVERED UNDER YOUR MEDICAL BENEFIT The following medications may be covered under your medical benefit if they are provided to you in your doctor s office or outpatient infusion

More information

5-ASA. Products Affected DIPENTUM 250 MG CAPSULE LIALDA 1.2 GRAM TABLET,DELAYED RELEASE. Details

5-ASA. Products Affected DIPENTUM 250 MG CAPSULE LIALDA 1.2 GRAM TABLET,DELAYED RELEASE. Details 5-ASA DIPENTUM 250 MG CAPSULE LIALDA 1.2 GRAM TABLET,DELAYED You are required to have previous therapy with balsalazide, Delzicol, Apriso, or Asacol HD before we will cover Lialda or Dipentum. 1 ANTIEMETICS

More information

5-ASA. Products Affected. Details. Dipentum 250 mg capsule. Lialda 1.2 gram tablet,delayed release

5-ASA. Products Affected. Details. Dipentum 250 mg capsule. Lialda 1.2 gram tablet,delayed release Updated 11/1/17 5-ASA Dipentum 250 mg capsule Lialda 1.2 gram tablet,delayed release You are required to have previous therapy with balsalazide, Delzicol, Apriso, or Asacol HD before we will cover Lialda

More information

Granite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18

Granite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18 Granite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18 Granite Alliance requires step therapy for certain drugs. This means prior to receiving a drug with a step therapy

More information

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process Quality ID #337: Psoriasis: Tuberculosis (TB) Prevention for Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis on a Biological Immune Response Modifier National Quality Strategy Domain:

More information

STEP THERAPY CRITERIA

STEP THERAPY CRITERIA CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)

More information

PRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION

PRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION Abstral fentanyl citrate oral tablet Controlled Dangerous substance Actemra tocilizumab Monoclonal antibody Acthar corticotropin Hormone Actimmune interferon gamma 1b Interferon Actiq fentanyl citrate

More information

Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary

Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary Biologic Immunomodulators Prior Authorization with Quantity Limit (with a preferred option) OBJECTIVE The intent of the

More information

Specialty Drugs. The following is a list of medications that are considered to be specialty drugs. Specialty drugs

Specialty Drugs. The following is a list of medications that are considered to be specialty drugs. Specialty drugs Specialty Drugs The following is a list of medications that are considered to be specialty drugs. Specialty drugs include self-administered injectables, medications that are high cost, and/or medications

More information

RPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics

RPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics Nov/Dec 2015 Issue 11 RPCC Pharmacy Forum Special Interest Articles: Diabetes Medication Chart Insulin Chart Afreeza Did you know? Exanatide, marketed as Byetta, is the synthetic form of exendin-4, which

More information

TRICARE Uniform Formulary. Pre-Authorization Requirements

TRICARE Uniform Formulary. Pre-Authorization Requirements TRICARE Uniform Formulary Pre-Authorization Requirements The Department of Defense (DoD) requires pre-authorization on select medications. These medications are on the DoD s pre-authorization list because

More information

Oregon Health Plan prescription benefit updates

Oregon Health Plan prescription benefit updates Oregon Health Plan prescription benefit updates EOCCO s prescription program is a pharmacy benefit that offers members a choice of safe and effective medication treatments. The program also helps you save

More information

What the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin

What the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin Diabetes s Oral s - Pills These are some of the pills that are currently available in Canada to treat diabetes. Each medication has benefits and side effects you should be aware of. Your diabetes team

More information

Specialty Drugs. The specialty drug list below is effective June 5, 2018 and is subject to change at any time.

Specialty Drugs. The specialty drug list below is effective June 5, 2018 and is subject to change at any time. Specialty Drugs The following is a list of medications that are considered specialty drugs. Specialty drugs include self-administered injectables, medications that are high cost, and/or medications that

More information

Initiating Injectable Therapy in Type 2 Diabetes

Initiating Injectable Therapy in Type 2 Diabetes Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current

More information

FARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)

FARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin) Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your

More information

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority Quality ID #410: Psoriasis: Clinical Response to Systemic Medications National Quality Strategy Domain: Person and Caregiver-Centered Experience and Outcomes Meaningful Measure Area: Management of Chronic

More information

Objectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)

Objectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia) How Medicine Works to Control Blood Sugar Levels Stacie Petersen, RN, CDE Objectives Define Diabetes List how medications work (ominous octet) Identify side effects of medications for diabetes What is

More information

PRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION

PRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION Abstral fentanyl citrate oral tablet Controlled Dangerous substance Actemra tocilizumab Monoclonal antibody Acthar corticotropin Hormone Actimmune interferon gamma 1b Interferon Actiq fentanyl citrate

More information

2018 BCN Advantage Prior Authorization Criteria Last updated: November, 2017

2018 BCN Advantage Prior Authorization Criteria Last updated: November, 2017 Abstral Actemra Adcirca Adempas Afinitor Afinitor- Disperz Alecensa Alunbrig Amitiza Amitriptyline Ampyra Anadrol-50 Androgel Androderm Aralast NP Aranesp Arcalyst Armodafinil Aubagio Avonex Bavencio Beleodaq

More information

2018 BCN Advantage Prior Authorization Criteria Last updated: April, 2018

2018 BCN Advantage Prior Authorization Criteria Last updated: April, 2018 Abstral Actemra Adcirca Adempas Aliqopa Afinitor Afinitor- Disperz Alecensa Alunbrig Amitiza Amitriptyline Ampyra Anadrol-50 Androgel Androderm Aralast NP Aranesp Arcalyst Armodafinil Aubagio Avonex Bavencio

More information

Specialty Pharmacy Pipeline

Specialty Pharmacy Pipeline Specialty Pharmacy Pipeline Drugs to Watch Anticipated Launches Q1 Q2 2017 Atopic Dermatitis Dupixent (dupilumab) Subcutaneous injection Regeneron Pharmaceuticals/Sanofi moderate-to-severe atopic dermatitis

More information

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 8 Last Review Date: March 16, 2018 Orencia Description Orencia (abatacept)

More information

Cosentyx. Cosentyx (secukinumab) Description

Cosentyx. Cosentyx (secukinumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.11 Subject: Cosentyx Page: 1 of 7 Last Review Date: September 20, 2018 Cosentyx Description Cosentyx

More information

March 2017 Pharmacy & Therapeutics Committee Decisions

March 2017 Pharmacy & Therapeutics Committee Decisions UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to the UCare formulary (approved drug list). These changes are reviewed

More information

DIABETES (1 of 5) Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10. Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10 $0 $0 $0

DIABETES (1 of 5) Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10. Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10 $0 $0 $0 Metformin DIABETES (1 of 5) Glucophage Glucophage XR ER $7 (500mg) $7 (500mg) $5 $5 500mg, 750mg only 500mg, 750mg only Sulfonylurea/Combinations Amaryl Glucotrol glimepiride glipizide $5 $5 Glucotrol

More information

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review

More information

MedStar Medicare Choice Pharmacy Services

MedStar Medicare Choice Pharmacy Services Pharmacy Services 1 MedStar Medicare Choice Pharmacy Services Table of Contents At a Glance..page 2 Pharmacy Policies..page 4 Medicare Choice Pharmacy Programs..page 6 Where to Obtain Prescriptions..page

More information

Pharmacologic Agents for Treatment of Type 2 Diabetes

Pharmacologic Agents for Treatment of Type 2 Diabetes Pharmacologic Agents for Treatment of Type 2 Diabetes SCAN Drugs Medication Biguanides 1 1 er uncoated tabs 500 mg & 750 mg Sulfonylureas 1 1 500 850 mg QD - TID 500 2000 mg glimepiride 1 1 1 8 mg glipizide

More information

Regulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1)

Regulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.12 Subject: Entyvio Page: 1 of 7 Last Review Date: September 20, 2018 Entyvio Description Entyvio

More information

Prior Authorization Program Information (Effective April 1st, 2018)

Prior Authorization Program Information (Effective April 1st, 2018) Prior Authorization Program Information (Effective April 1st, 2018) Prior Authorization Certain drugs require prior authorization to help promote safe, quality and affordable pharmacy care. Your doctor

More information

Collaborative Practice Agreement

Collaborative Practice Agreement Collaborative Practice Agreement [community pharmacy name] [address] [phone number] [physician practice] [address] [phone number] Effective: [date] Expiration: [date] 1 Table of Contents 1.0 Introduction...4

More information

Pharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17

Pharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17 Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)

More information

Prescription benefit updates Large group

Prescription benefit updates Large group Prescription benefit updates Large group Moda Health s prescription program is a pharmacy benefit that offers members a choice of safe effective medication treatments. The program also helps you save money

More information

Step Therapy Criteria 2019

Step Therapy Criteria 2019 Step Therapy 2019 For information on obtaining an updated coverage determination or an exception to a coverage determination please call Freedom Health Member Services at 1-800-401-2740 or, for TTY/TDD

More information

Management of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism

Management of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism Management of Type 2 Diabetes Mellitus Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism Disclosures Working for Intermountain Healthcare Some of the views represented are the opinion of ABIM-certified

More information

Regulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)

Regulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Orencia Page: 1 of 9 Last Review Date: September 20, 2018 Orencia Description Orencia (abatacept)

More information

CIMZIA (certolizumab pegol)

CIMZIA (certolizumab pegol) Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Otezla (apremilast) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Otezla (apremilast) Prime Therapeutics will review Prior Authorization requests Prior

More information

Prescription Drug Benefit Rider

Prescription Drug Benefit Rider Prescription Drug Benefit Rider Your Certificate of Coverage is amended as described in this document. This Rider becomes a part of your Certificate of Coverage and is subject to all provisions of your

More information

Mountain Health Trust/WV Health Bridge

Mountain Health Trust/WV Health Bridge Mountain Health Trust/WV Health Bridge Preferred Drug List (PDL) The West Virginia Preferred Drug List (PDL) is a list of medications recommended to BMS by the West Virginia Medicaid Pharmaceutical and

More information

ACTEMRA (tocilizumab)

ACTEMRA (tocilizumab) Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 1. Active Polyarticular Juvenile Idiopathic Arthritis (PJIA) b. Patient has an intolerance or has experienced

More information

Drug Bill As Unit Common Directions Common Day Supply Common Billing Errors Oral Tablets/Capsules

Drug Bill As Unit Common Directions Common Day Supply Common Billing Errors Oral Tablets/Capsules Note: This is a guide for commonly misbilled medications. Please submit the claims according to directions for use indicated on the prescription order. Drug Bill As Unit Common Directions Common Day Supply

More information

Prescription Drug Benefit Rider V

Prescription Drug Benefit Rider V Prescription Drug Benefit Rider V Your Certificate of Coverage is amended as described in this document. This Rider becomes a part of your Certificate of Coverage and is subject to all provisions of your

More information

Thank you for your request for information that has been processed under reference number

Thank you for your request for information that has been processed under reference number Corporate Development Contact us: dhft.foi@nhs.net Royal Derby Hospital Uttoxeter Road Derby DE22 3NE Tel: 01332 265500 Minicom: 01332 785566 www.derbyhospitals@nhs.uk Follow us on Twitter @DerbyHospitals

More information

HEALTH SHARE/PROVIDENCE (OHP)

HEALTH SHARE/PROVIDENCE (OHP) HEALTH SHARE/PROVIDENCE (OHP) STEP THERAPY This is a complete list of drugs that have written coverage determination policies. Drugs on this list do not indicate that this particular drug will be covered

More information

Otezla. Otezla (apremilast) Description

Otezla. Otezla (apremilast) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Otezla Page: 1 of 5 Last Review Date: March 16, 2018 Otezla Description Otezla (apremilast) Background

More information

Stelara. Stelara (ustekinumab) Description

Stelara. Stelara (ustekinumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 9 Last Review Date: September 20, 2018 Stelara Description Stelara

More information

What s New in Type 2 Diabetes? 2018 Diabetes Updates

What s New in Type 2 Diabetes? 2018 Diabetes Updates What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most

More information

This program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.

This program applies to Commercial, GenPlus and Health Insurance Marketplace formularies. OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) Agonists [Adlyxin (lixisenatide), Byetta (exenatide), Bydureon (exenatide extended-release), Tanzeum (albiglutide), Trulicity (dulaglutide),

More information

OptumRx Focused Utilization Management Program

OptumRx Focused Utilization Management Program Utilization management updates - January 1, 2019 OptumRx Focused Utilization Management Program OptumRx focused step therapy with quantity limits programs If you have a prescription for any of the Step

More information

HEALTHTEAM ADVANTAGE 2018 Step Therapy Criteria

HEALTHTEAM ADVANTAGE 2018 Step Therapy Criteria GLP1-INSULIN XULTOPHY SOLUTION PEN- INJECTOR 100-3.6 UNIT-MG/ML Claim will pay automatically for Xultophy if enrollee has a paid claim for at least a one day supply for step level 1 agent (LANTUS, LEVEMIR,

More information

Technician Tutorial: Dispensing Insulin and Other Injectable Meds

Technician Tutorial: Dispensing Insulin and Other Injectable Meds (Page 1 of 6) Technician Tutorial: Dispensing Insulin and Other Injectable Meds Insulin is a hormone secreted by the pancreas. It helps the body use glucose as an energy source. Insulin acts like a key

More information

HEALTHTEAM ADVANTAGE 2018 Step Therapy Criteria

HEALTHTEAM ADVANTAGE 2018 Step Therapy Criteria GLP1-INSULIN XULTOPHY SOLUTION PEN- INJECTOR 100-3.6 UNIT-MG/ML HEALTHTEAM ADVANTAGE Claim will pay automatically for Xultophy if enrollee has a paid claim for at least a one day supply for step level

More information

Xeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description

Xeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 6 Last Review Date: March 16, 2018 Xeljanz Description Xeljanz, Xeljanz

More information

Images have been removed from the PowerPoint slides in this handout due to copyright restrictions. Insulins. Rapid Short Intermediate Long Mix

Images have been removed from the PowerPoint slides in this handout due to copyright restrictions. Insulins. Rapid Short Intermediate Long Mix Diabetes Medications Diabetes Medications Type 1 Insulin is needed Type 2 Oral Diabetes Medications Or Oral Diabetes Medications plus Insulin Or Insulin Alone Diabetes Medications Secretagogues Glipizide

More information

These programs and quantity limitations may not apply. Check your certificate or other plan information for benefit details.

These programs and quantity limitations may not apply. Check your certificate or other plan information for benefit details. FlexRx Standard Utilization Management (PA, QL,) Updates January 1, 2018 How to use this drug list This drug list includes updates to Utilization Management (UM) programs. UM may include a prior authorization

More information

New Billing Guidelines for Home Infusion, Enteral and Parenteral Therapies Home Infusion Fee Schedule Effective July 1, 2009

New Billing Guidelines for Home Infusion, Enteral and Parenteral Therapies Home Infusion Fee Schedule Effective July 1, 2009 STAT Bulletin PO Box 80 Buffalo, New York 14240-0080 May 12, 2009 Volume 15:Issue 18 To: All Home Health Care and Home Infusion Therapy Providers Contracts Effected: All Lines of Business New Billing Guidelines

More information

DPP4 INHIBITORS. Details. Step Therapy Criteria Health Alliance Plan 2019 Date Effective: 04/01/2019

DPP4 INHIBITORS. Details. Step Therapy Criteria Health Alliance Plan 2019 Date Effective: 04/01/2019 DPP4 INHIBITORS Janumet 50 mg-1,000 mg tablet Januvia 50 mg tablet Janumet 50 mg-500 mg tablet Onglyza 2.5 mg tablet Januvia 100 mg tablet Onglyza 5 mg tablet Januvia 25 mg tablet Tradjenta 5 mg tablet

More information

What s New in Type 2 Diabetes? 2018 Diabetes Updates

What s New in Type 2 Diabetes? 2018 Diabetes Updates What s New in Type 2 Diabetes? 2018 Diabetes Updates Jessica Conklin, PharmD, PhC, BCACP, CDE, AAHIP Associate Professor, UNM College of Phar macy jeconklin@salud.unm.edu Luis Gonzales, PharmD, PhC UNM

More information

Injectable Therapies in Diabetes

Injectable Therapies in Diabetes Injectable Therapies in Diabetes Diabetes Specialist Nurse Linda Burns Learning Outcomes Understand the place of injectible therapies in diabetes Understand when patients may require insulin therapy Consider

More information

5-ASA. Products Affected Dipentum 250 mg capsule. Details. Lialda 1.2 gram tablet,delayed release

5-ASA. Products Affected Dipentum 250 mg capsule. Details. Lialda 1.2 gram tablet,delayed release 5-ASA Dipentum 250 mg capsule Lialda 1.2 gram tablet,delayed release You are required to have previous therapy with balsalazide, Delzicol, Apriso, or Asacol HD before we will cover Lialda or Dipentum.

More information

DPP4 INHIBITORS. Products Affected Step 2: Janumet 50 mg-1,000 mg tablet Janumet 50 mg-500 mg tablet Januvia 100 mg tablet Januvia 25 mg tablet

DPP4 INHIBITORS. Products Affected Step 2: Janumet 50 mg-1,000 mg tablet Janumet 50 mg-500 mg tablet Januvia 100 mg tablet Januvia 25 mg tablet DPP4 INHIBITORS Janumet 50 mg-1,000 mg tablet Janumet 50 mg-500 mg tablet Januvia 100 mg tablet Januvia 25 mg tablet Januvia 50 mg tablet Onglyza 2.5 mg tablet Onglyza 5 mg tablet Tradjenta 5 mg tablet

More information

TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations

TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations 177 TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary Coverage Indication for use with: INSULIN THERAPY NS NB NL PE ADULTS PEDIATRICS PREGNANCY BOLUS

More information

Diabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items

Diabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items Diabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items Hayley A. Miller, MD Physician, Internal Medicine, Diabetes and Metabolism, Sandy Clinic, Intermountain Healthcare Objectives:

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Tysabri) Reference Number: HIM.PA.SP17 Effective Date: 05.01.17 Last Review Date: 05.18 Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important Reminder

More information

RHEUMATOID ARTHRITIS DRUGS

RHEUMATOID ARTHRITIS DRUGS Rheumatology Biologics Criteria from the Exceptional Access Program RHEUMATOID ARTHRITIS DRUGS DRUG NAME BRS REIMBURSED DOSAGE FORM/ STRENGTH Adalimumab Humira 40 mg/0.8 syringe and 40mg/0.8 pen for Anakinra

More information

Making Sense of New DM Therapies and Technologies

Making Sense of New DM Therapies and Technologies Making Sense of New DM Therapies and Technologies Sandra Indacochea Sobel, MD Clinical Assistant Professor of Medicine Clinical Chief of Endocrinology, UPMC Mercy Division of Endocrinology, Diabetes, and

More information

Premixed Insulin for Type 2 Diabetes. a gu i d e f o r a d u lt s

Premixed Insulin for Type 2 Diabetes. a gu i d e f o r a d u lt s Premixed Insulin for Type 2 Diabetes a gu i d e f o r a d u lt s March 2009 What This Guide Covers / 2 Type 2 Diabetes / 3 Learning About Blood Sugar / 4 Learning About Insulin / 5 Comparing Medicines

More information

!"#$%&%'(!)*+'(,(&)%-!'(.#!%('"./0%(( /1#).!(&2()!(((

!#$%&%'(!)*+'(,(&)%-!'(.#!%('./0%(( /1#).!(&2()!((( !"#%&%'(!)*+'(,(&)%-!'(.#!%('"./0%(( /1#).!(&2()!((( 26%5&"7%'( At the end of this presentation, participants should be able to: Evaluate the emerging role of GLP-1 Agonists for weight loss Understand

More information

UPMC for You Pharmacy and Therapeutics Committee Meeting April 7, 2014 meeting

UPMC for You Pharmacy and Therapeutics Committee Meeting April 7, 2014 meeting UPMC for You Pharmacy and Therapeutics Committee Meeting April 7, 2014 meeting 1. Call to order: The meeting was called to order at 7:05 a.m. 2. Review of the minutes: The minutes of the January meeting

More information

Cimzia. Cimzia (certolizumab pegol) Description

Cimzia. Cimzia (certolizumab pegol) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review

More information

Clinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date:

Clinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date: Clinical Policy: (Tysabri) Reference Number: ERX.SPA.162 Effective Date: 10.01.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Injectable Therapies in Diabetes

Injectable Therapies in Diabetes Injectable Therapies in Diabetes Diabetes Specialist Nurse Joyce Robson Learning Outcomes Think about the place of injectible therapies in diabetes Insulin therapy GLP1 antagonists Consider commonly used

More information

DRUGS REQUIRING PRIOR AUTHORIZATION

DRUGS REQUIRING PRIOR AUTHORIZATION DRUGS REQUIRING PRIOR AUTHORIZATION Medication Abstral Actemra Acthar Gel Actiq* Adcirca Adderall Adderall XR Addyi Adempas Adipex* Adzenys XR-ODT Afinitor Afinitor Alecensa Alecensa Ampyra Androderm AndroGel

More information

Step Therapy Requirements. Effective: 12/01/2016

Step Therapy Requirements. Effective: 12/01/2016 Effective: 12/01/2016 H2986_PD_049 Updated 11/2016 ALPHA 1-PROTEINASE INHIBITOR GLASSIA PRIOR CLAIM FOR ARALAST NP OR ZEMAIRA WITHIN THE PAST 120 DAYS. ANALGESICS, NARCOTICS KADIAN MORPHINE SULFATE ER

More information

Blue Cross and Blue Shield of Minnesota GenRx Formulary Updates

Blue Cross and Blue Shield of Minnesota GenRx Formulary Updates Blue Cross and Blue Shield of Minnesota GenRx Formulary Updates July 2018 TRADE NAME (generic name) or generic name ADVAIR DISKUS (fluticasone-salmeterol aer powder ba 100-50 mcg/dose) Brand Addition ADVAIR

More information

Physician Drug Reference Chart for Diabetes Antidiabetic Medications

Physician Drug Reference Chart for Diabetes Antidiabetic Medications Drug Class Compound Brand Name Mechanism of Action Advantages Disadvantages Alpha-glucosidase inhibitors Medium Cost by Bayer Healthcare, Pfizer, Takeda Research Acarbose Miglitol Voglibose Precose Glyset

More information

DIFICID. Products Affected Step 2: DIFICID TABLET 200 MG ORAL. Details

DIFICID. Products Affected Step 2: DIFICID TABLET 200 MG ORAL. Details DIFICID DIFICID TABLET 200 MG ORAL Claim will pay automatically for Dificid if enrollee has a paid claim for at least a 1 days supply of vancomycin in the past. Otherwise, Dificid requires a step therapy

More information

CENTENE PHARMACY & THERAPEUTICS COMMITTEE SECOND QUARTER 2017 AMBETTER GUIDELINE SUMMARY. Revision Summary or Description

CENTENE PHARMACY & THERAPEUTICS COMMITTEE SECOND QUARTER 2017 AMBETTER GUIDELINE SUMMARY. Revision Summary or Description CENTENE PHARMACY & THERAPEUTICS COMMITTEE SECOND QUARTER 2017 AMBETTER GUIDELINE SUMMARY Coverage Guideline Policy & Procedure HIM.PA.32 Long acting stimulants (Adderall XR, Dexedrine, Metadate CD, Ritalin

More information

INSULIN OVERVIEW. Type Brand Name Onset Peak Duration Role in glucose management Page Rapid-Acting lispro min. 3-5 hrs min.

INSULIN OVERVIEW. Type Brand Name Onset Peak Duration Role in glucose management Page Rapid-Acting lispro min. 3-5 hrs min. INSULIN OVERVIEW Type Brand Name Onset Peak Duration Role in glucose management Page Rapid-Acting lispro Humalog 15-30 min 30-90 min 3-5 hrs aspart glulisine Short-Acting Regular insulin NovoLog Apidra

More information

Clinical Policy: Natalizumab (Tysabri) Reference Number: CP.PHAR.259 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Natalizumab (Tysabri) Reference Number: CP.PHAR.259 Effective Date: Last Review Date: Line of Business: Medicaid Clinical Policy: (Tysabri) Reference Number: CP.PHAR.259 Effective Date: 07.01.16 Last Review Date: 05.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of

More information

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES Generic Brand HICL GCN Exception/Other SOMATROPIN HUMATROPE GENOTROPIN NORDITROPIN NORDITROPIN FLEXPRO NORDITROPIN NORDIFLEX NUTROPIN NUTROPIN AQ OMNITROPE SAIZEN ZOMACTON 02824 BRAND ZORBTIVE BRAND SEROSTIM

More information

Injectable Drugs Requiring Pre-Service Approval

Injectable Drugs Requiring Pre-Service Approval Abatacept Orencia J0129, 10 mg 1500 FL LCD- L29051 1) For patients with rheumatoid arthritis with failure, intolerance or contraindications to methotrexate. Limit dosing to 40 mg Q 2 weeks. 2) For patients

More information

TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations

TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations 177 TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary

More information

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy

More information